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Clostridium difficile is responsible for 15–25% of cases of antibiotic-associated diarrhea (AAD) and for virtually all
cases of antibiotic-associated pseudomembranous colitis (PMC). This anaerobic bacterium has been identified as
the leading cause of nosocomial infectious diarrhea in adults and can be responsible for large outbreaks.
Nosocomial C. difficile infection results in an increased length of stay in hospital ranging from 8 to 21 days. Risk
factors for C. difficile-associated diarrhea include antimicrobial therapy, older age (>65 years), antineoplastic
chemotherapy and length of hospital stay. Other interventions with high risk associations are enemas, nasogastric
tubes, gastrointestinal surgery and antiperistaltic drugs. Prospective studies have shown that nosocomial
transmission of C. difficile is frequent but often remains asymptomatic. Patients can be contaminated from
environnemental surfaces, shared instrumentation, hospital personnel hands and infected roommates. Once an
outbreak starts, C. difficile may be spread rapidly throughout the hospital environment where spores may persist
for months. Measures that are effective in reducing incidence of C. difficile infections and cross-infection include:
(i) an accurate and rapid diagnosis, (ii) appropriate treatment, (iii) implementation of enteric precautions for
symptomatic patients, (iv) reinforcement of hand-washing, (v) daily environmental disinfection, and (vi) a
restrictive antibiotic policy. C. difficile is a common cause of infectious diarrhea and should be therefore
systematically investigated in patients with nosocomial diarrhea.
Keywords Clostridium difficile, diarrhea, colitis, nosocomial infections, epidemiology
Clin Microbiol Infect 2001; 7: 405–410
INTRODUCTION
Clostridium difficile is a spore-forming Gram-positive anaerobic
bacillus that was first isolated from stools of neonates in 1935.
Forty years later, this bacterium has been recognised as the main
cause of pseudomembranous colitis (PMC) and antibiotic-
associated colitis and diarrhea—the C. difficile-associated disease
(CDAD) [1,2]. Since then, studies concerning the pathogenesis,
diagnosis and treatment of C. difficile-associated infections have
increasingly been reported. In this paper, we review the current
knowledge of epidemiological features related to C. difficile.
CLINICAL PRESENTATIONS
Clinical presentations of C. difficile range from mild diarrhea to
life-threatening PMC with megacolon and possible perforation.
C. difficile toxin B has been isolated from stools of more than
95% of PMC cases and of 15–25% cases of antibiotic-associated
diarrhea (AAD) (Table 1) [1]. During the past 20 years, toxi-
genic C. difficile has emerged as a major cause of nosocomial
diarrhea and has been responsible for large outbreaks in hospital
settings [3,4]. In many hospitals, C. difficile is the most common
enteropathogen isolated from stool cultures.
However, isolation of C. difficile must be interpreted with
caution because asymptomatic carriage is usually observed in
less than 3% of healthy adults [1]. Carriage rates are higher in
patients with previous hospitalisation or in patients who have
previously received antibiotics. It is not known if this carriage
rate represents transient colonisation or a component of the
stable flora.
Pathogenesis
More than 90% of C. difficile infections occur after or during
antibiotic treatment. Antibiotics act by disrupting the normal
colonic flora, allowing C. difficile, from endogenous or exo-
genous origins, to establish itself in the colon and proliferate. If
the strain is toxigenic, toxins A and B are produced simulta-
neously in almost all cases, causing fluid secretion, inflammation
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and mucosal damage, leading to diarrhea or PMC. The precise
mechanism of action of toxins is detailed elsewhere in this issue
[6]. The reasons why patients may present either with a mild
diarrhea or PMC still remain unclear but the clinical outcome
probably depends on other virulence factors such as adhesion or
hydrolytic enzyme secretion and host factors [5,7].
Risk factors
To date, almost all antibiotics, except for aminoglycosides given
intravenously, have been incriminated in the development of
CDAD. In a recent meta-analysis performed by Bignardi et al.
[8], a systematic review of the literature enabled individual
antibiotics to be ranked in relation to the risk of C. difficile
infection. The antibiotics most frequently implicated were the
broad-spectrum antibiotics that have a large impact on the
normal intestinal flora, particularly when given orally [8,9].
These include penicillins, penicillins associated with a b-lacta-
mase inhibitor, cephalosporins and clindamycin. A combi-
nation of antibiotics or long duration of the course increases
the risk of developing the disease. CDAD can also be induced
by antibiotics to which C. difficile is susceptible in vitro.
This paradox still remains unclear but it might be partially
explained by an overgrowth of C. difficile from persistent
spores at a faster rate than the restoration of the normal colonic
flora.
Other independent risk factors for the development of
CDAD were identified in case–control studies (Table 2) [10–
15]. Factors that have been significantly associated with CDAD
in multivariate analyses include patients older than 65 years or
Table1 Rates of recovery ofClostridium difficile and percentages of positive assay for toxin in stool from various populations (adapted from [1])
Patients Isolation rate (%) Positive toxin assay (%)
Patients with pseudomembranous colitis 95^100 95^100
Patients with antibiotic-associated diarrhea 15^25 10^25
Patients without diarrhea but with previous antibiotic administration 10^20 5^10
Hospitalised patients 10^25 2^8
Healthy adults <3 <0.5
Healthy neonates 5^70 5^63
Table 2 Risk factors for Clostridium difficile infections (multivariate analysis)
Reference
(year) No. of patients Risk factors Odds ratio (CI 95%)
Brown et al. (1990) [10] 37 cases Age>65 114.1 (1.4^141)
37 controls ICU 39.2 (2.2^713)
ATB>10days 16.1 (2.2^117)
Gastrointestinal procedure 23.2 (2.1^255)
McFarland et al. (1990) [9] Cohort Cephalosporins 3rd G 2.07 (1.11^3.04)a
399 patients Enemas 3.26 (1.51^7.02)a
Stool softeners 1.74 (1.02^3)a
Penicillins 3.41 (1.48^7.46)a
Barbut et al. (1997) [11] 34 cases CD4<50/mm3 5.2 (1.4^19.3)
66 controls Clindamycin 5 (1.3^18.3)
Penicillins 4.6 (1.1^18.8)
Thibault et al. (1991) [12] 26 cases Number of ATB 1.6 (1.1^2.4)
26 controls Digestive surgery 4.7 (1^21)
Hutin et al. (1993) [13] 19 cases Clindamycin 42 (2^813)
38 controls Length of hospital stay 3.6/week (1^13)
Watanakunakorn et al. (1996) [14] 91cases Cephalosporins 4.2 (2.16^8.29)
91controls
Talon et al. (1995) [15] 21cases b-lactams 4.92 (1.59^16.9)
63 controls Pristinamycin 7.95 (1.71^45.1)
Enteral feeding 19.7 (1.9^118.1)
aResults expressed as relative risk (RR) factors.
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with a severe underlying illness, performance of non-surgical
gastrointestinal procedures, such as nasogastric tube, stool soft-
eners, anti-ulcer medications and enemas. Many of these risk
factors have a common characteristic of interfering with the
barrier effect exerted by the normal stable flora. Other factors
such as the intensive care unit (ICU) or the duration of stay in
the hospital may reflect a greater exposure to C. difficile.
Administration of antineoplasic chemotherapy has never been
identified per se as an independant risk factor for CDAD in
cohort or case–control studies, but several case reports suggest
that chemotherapy, apart from any concomitant antibiotic
treatment, could precipitate CDAD [16].
Incidence of C. difficile infections
Most studies concerning C. difficile infections have been per-
formed in hospital settings. Little attention has been paid to the
role of C. difficile as a potential cause of diarrhea in the
community. The incidence of C. difficile infection in the com-
munity has been estimated at 8/100 000 patients per year but
this result is biased by the absence of a systematic search for C.
difficile [17]. A recent prospective French study performed by
Beaugerie et al. [18] in 260 adults under the care of their general
practitioner showed that antibiotic-associated diarrhea is fre-
quent and is observed in 17.5% of patients. Among these
patients, a toxigenic strain of C. difficile has been found in
8.7% of cases compared to only 1.4% in patients without
diarrhea (P< 0.02). One can extrapolate from these results that
C. difficile is responsible for 1.5% of post-antibiotic diarrhea in
the community, and we can estimate, from the general anti-
biotic use in France, that approximately 920 000 people per year
(CI 95%, 230 000–2 300 000) develop a diarrhea with a toxi-
genic strain of C. difficile.
The incidence of CDAD among hospitalised patients has
been found to vary widely, from 0.1 to 2% [19–21]. These
incidences include patients with severe C. difficile-associated
diarrhea who required hospitalisation and patients with C.
difficile nosocomial infection. In the study performed by Olson
et al. [20], the total number of C. difficile cases in 10 years was
908, leading to an annual incidence ranging from 0.4 to 1%. In
this study, 93% of cases were classified as nosocomially acquired.
In the study of Bowen et al. [19], the incidence was 0.42% but
the rate of C. difficile cases was higher for bone marrow
transplant recipients and patients who had undergone cardi-
othoracic surgery. In Saint-Antoine Hospital in Paris, the
annual incidence of CDAD is much lower and ranges from
0.07 to 0.12 per 100 admissions but higher rates are observed in
the ICU, oncology or hematology departments (personal data).
More than 70% of the cases were considered to be nosocomially
acquired.
Carriage and acquition rates
If the incidence of C. difficile infections seems relatively low in
hospital, carriage and acquisition rates of C. difficile are much
higher. Many teams have focused on the transmission rate of C.
difficile through prospective studies in which patients were
systematically screened for C. difficile shortly after their admis-
sion into hospital, and then once or twice weekly thereafter
(Table 3) [3,21–24]. In these studies, carriage rates at admission
range from 5.9 up to 11%. This is a higher rate than the 3%
reported in healthy adults, and may reflect the previous admin-
istration of antibiotics or the nosocomial acquisition of C.
difficile during previous hospitalisations.
The rate of C. difficile acquisition varies with the patient
population studied, the use of antibiotics and the presence of an
outbreak in the ward studied. In the absence of outbreak, the
acquisition rate has been estimated at 4–21% but this acquisition
remains asymptomatic in more than 63% of cases. Nevertheless,
during outbreaks, higher acquisition rates have been observed,
such as 32% in the study performed by Delme´e et al. in a
hematology ward [24]. These results illustrate the explosive
potential of C. difficile dissemination in the hospital setting.
Once introduced by a CDAD index patient, C. difficile can be
responsible for outbreaks in wards where there is clustering
of susceptible patients. Transmission of C. difficile from patient
Table 3 Results of prospective studies estimating the carriage rate and acquisition rate ofClostridium difficile
Reference
(year) Wards
Period
(months) No. of patients
Carriage
rate (%)
Acquisition
rate (%)
McFarland et al. (1989) [3] Medical 11 428 7 21a
Tabaqchali et al. (1992) [21] Geriatric 6 68 5.9 4.4
Samore et al. (1994) [22] MedicalþSurgicalþ ICU 5 496 11 15b
Clabots et al. (1992) [23] MedicalþSurgical 9 634 10.2 8.5c
Delme¤ e et al. (1987) [24] Haematology 6 62 7.7 32.2
Tabaqchali et al. (1992) [21] Haematology 6 13 6.6 21.5
Tabaqchali et al. (1992) [21] Geriatric 6 54 11.1 14.8
a63% of asyptomatic colonisation; b73.5% of asymptomatic colonisation; c95% of asymptomatic colonisation. ICU: intensive care unit.
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to patient has been confirmed by molecular typing methods
[25].
C. difficile as themain agent of nosocomial diarrhea
Different studies showed that C. difficile was a major agent of
nosocomial diarrhea in adults [26–28]. The frequency of C.
difficile or toxins in stool culture prescribed at least 3 days after
patients’ admission (therefore corresponding to a suspected
nosocomial diarrhea) are summarised in Table 4. C. difficile or
toxins are recovered from 8–10% of nosocomial diarrhea,
whereas other common enteric pathogens such as Salmonella
spp., Shigella spp. and Campylobacter spp. are very seldom
implicated in nosocomial diarrhea in industrialised countries.
These results led the American Society for Microbiology to
establish recommendations for stool culture. Stool culture for
common enteric pathogens should not be performed in patients
hospitalised for more than 3 days unless there are plausible
clinical or epidemiological reasons to do so. In contrast, testing
for C. difficile should be systematically requested for such
patients.
Clinical impact of C. difficile infections
Mortality associated with C. difficile infections has been esti-
mated by Olson et al. [20] in a retrospective study of 908 C.
difficile infections: they found that six patients (0.6%) died with
active PMC colitis as a primary factor in mortality. In another
study, Morris et al. [29] showed that the mortality of patients
requiring colectomy for toxic megacolon or for a colon per-
foration was high and ranged from 35 to 50%.
C. difficile infection has been shown to increase the length of
stay in hospital by 8 days in adult inpatients and by 36 days in
geriatric patients [3,30].
Few data exist on the cost associated with C. difficile infec-
tions. Wilcox et al. [31] performed a prospective case–control
study in a Cambridge hospital and found that the approximate
additional cost of a C. difficile infection was UK£4107 (6520
Euros). Actually, 94% of the calculated extra cost resulted from
prolonged hospital stay. Other consequences, such as possible
ward closure, loss of bed days, or infection control measures
were not generally taken into account.
RESERVOIRS, SOURCES AND TRANSMISSION
OF C. DIFFICILE
The major reservoirs for C. difficile in the hospital setting are
patients with CDAD or asymptomatic carriers of C. difficile.
Patients with symptomatic disease heavily contaminate their
immediate hospital environment and the spores can persist for
several months on surfaces. Shedding of C. difficile into the
environment depends on the patient’s status. McFarland et al.
[3] compared the rate of environmental contamination in rooms
of patients with C. difficile-associated diarrhea to that of con-
tamination in rooms of C. difficile asymptomatic carriers. They
showed that contamination was significantly higher in rooms of
patients with diarrhea compared to asymptomatic carriers (49
vs. 29%). They also analyzed contamination in rooms without
C. difficile-positive patients and found a contamination rate of
8%, showing that spores of C. difficile can persist, despite routine
cleaning of rooms.
Transmission of C. difficile is thought to occur via the oro–
fecal route. Outbreaks in hospitals and typing of strains sug-
gested that transmission is probably via staff hands. A study
documented positive hand cultures in 59% of hospital personnel
caring for patients with positive culture [3]. Transmission can
also occur by direct contact with contaminated surfaces. Some
reports also suggested a transmission by direct inoculation into
the bowel via contaminated materials such as thermometers
[32]. Factors that may explain the ease of transmission include
resistance of the spores to the most commonly used disinfectants
and antiseptics, the antibiotic pressure in hospitalised patients
and the promiscuity of patients. Unrecognised patients with C.
difficile, or re-admissions of patients with C. difficile, can con-
tribute to the reintroduction and spread of C. difficile to other
patients or the environment. Clabots et al. [23], using restriction
endonuclease as a typing method, showed that 84% of cases of
nosocomial acquisition of C. difficile strains were preceded by a
documented introduction of the strain to the ward by another
asymptomatic admission.
PREVENTION OF CROSS- INFECTION
Prevention of cross-infection requires constant awareness of C.
difficile infection. The prompt diagnosis of CDAD is the first step
Table 4 Prevalence of Clostridium difficile and/or its toxins in patients suspected of having nosocomial diarrhea
Reference
(year) Design
Rate of common
enteric pathogensa
Rate of
C. difficile
Rate of
toxins
Fan et al. (1993) [26] Prospective 0/567 (0%) ^ 14/182 (8%)
Barbut et al. (1995) [27] Prospective 5/344 (1.5%) 35/344 (10.2%) ^
Rohner et al. (1998) [28] Retrospective 110/8052 (1.4%) 248/2531 (9.8%) ^
aSalmonella, Shigella, Campylobacter,Yersinia.
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to controling C. difficile dissemination. As soon as CDAD is
suspected or identified, full enteric precautions must be imple-
mented, and should be maintained until at least 48 h after the
diarrhea has stopped. Segregation of patients in private rooms
with private toilet facilities is highly recommended. In a pro-
spective study performed by Johnson et al. [33], the use of vinyl
gloves by personnel when handling body substances, in con-
junction with an educational program, resulted in a significant
decrease in the incidence of C. difficile and supports the recom-
mendation to use vinyl gloves. The disinfection of patients’ areas
with hypochlorite- or aldehyde-containing disinfectants has
been shown to be highly effective in reducing environmental
contamination [33,34] and thorough daily cleaning should
therefore be reinforced. In cases of severe diarrhea, treatment
of symptomatic patients is also recommended in order to
decrease shedding of the organism.
PREVENTION OF C. DIFFICILE INFECTIONS
Among measures aimed at preventing C. difficile infection,
restrictive use of antibiotics, especially those that are considered
at high risk for C. difficile infection, is absolutely necessary. This
measure has already proved effective in decreasing the incidence
of C. difficile infections [35]. Table 5 reports other interven-
tions to reduce CDAD that have been successfully implemented
in Belgium or the USA [32–35]. Several measures, such as
wearing vinyl gloves or cohorting patients with CDAD, the use
of disposable thermometers or the use of hypochlorite for
environmental disinfection have already been effective in
controlling outbreaks or decreasing incidence of C. difficile
infections.
Treatment of asymptomatic carriers is no longer recom-
mended. A randomised placebo-controlled study carried out
by Johnson et al. [36] in 1992 to compare the efficacy of
vancomycin or metronidazole for eradication of C. difficile
showed that asymptomatic fecal excretion was not affected
by metronidazole. More recently, Shim et al. [37] suggested
that previous asymptomatic colonisation might act as a protec-
tive factor for a subsequent CDAD. Nevertheless, these results
need to be confirmed.
C. difficile is the most common enteric pathogen in hospi-
talised patients. Transmission from patient to patient is very easy
and spores play a key role in cross-infection because they can
survive several months in the environment. Control measures
include strict antibiotic policy, a high degree of suspicion of
C. difficile, prompt diagnosis, isolation and treatment of
infected patients, and implementation of enteric precautions.
Surveillance should be instituted in order to detect outbreaks
early.
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